Get the Stockscreener App
92.92
0.01%
-0.01
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $92.92, with a volume of 19.44M.
It is down -0.01% in the last 24 hours and up +9.70% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$92.93
Open:
$92.2
24h Volume:
19.44M
Relative Volume:
1.62
Market Cap:
$232.09B
Revenue:
$63.90B
Net Income/Loss:
$19.05B
P/E Ratio:
12.29
EPS:
7.5596
Net Cash Flow:
$13.05B
1W Performance:
+7.70%
1M Performance:
+9.70%
6M Performance:
+26.47%
1Y Performance:
-5.53%
1-Day Range:
$91.49
$95.08
1-Week Range:
$85.80
$95.08
52-Week Range:
$73.31
$105.07
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
92.92 | 230.65B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
LLY
Lilly Eli Co
|
1,025.28 | 915.49B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
195.93 | 470.41B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
232.36 | 410.55B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.26 | 253.11B | 54.45B | 14.42B | 17.15B | 7.333 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Intech Investment Management LLC Trims Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Sculati Wealth Management LLC Reduces Holdings in Merck & Co., Inc. $MRK - MarketBeat
OmniStar Financial Group Inc. Has $1.10 Million Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Merck & Co., Inc. $MRK Stock Position Raised by Advisors Capital Management LLC - MarketBeat
Merck Offers $9.2bn To Buy Cidara And Phase III Antiviral Flu Preventative - Citeline News & Insights
Merck buys Cidara for $9.2B as Keytruda patent loss looms - BioWorld MedTech
Merck Buys Cidara For $9.2 Billion To Add Flu Drug - Finimize
Merck agrees $9.2bn deal for flu-prevention biotech Cidara - Financial Times
Merck to Acquire Cidara Therapeutics in $9.2 Billion Deal - Bloomberg.com
What's Going On With Merck Stock Friday?Merck & Co (NYSE:MRK), Cidara Therapeutics (NASDAQ:CDTX) - Benzinga
Merck to acquire Cidara Therapeutics for $9.2B - Proactive financial news
Do You Believe in Merck & Co.’s (MRK) Upside Potential? - Insider Monkey
Olympiad Research LP Makes New Investment in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. agreed to acquire Cidara Therapeutics, Inc.. - MarketScreener
Grandfield & Dodd LLC Has $15.28 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
Oak Harvest Investment Services Purchases 4,194 Shares of Merck & Co., Inc. $MRK - MarketBeat
Phoenix Wealth Advisors Cuts Position in Merck & Co., Inc. $MRK - MarketBeat
Good Life Advisors LLC Grows Position in Merck & Co., Inc. $MRK - MarketBeat
Impax Asset Management Group plc Sells 252,213 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck to acquire Cidara for $221.50/share in $9.2 billion deal; CDTX soars (MRK:NYSE) - Seeking Alpha
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent - Business Wire
MerckBacillus of Calmette and Guerin (BCG) Vaccine for Percutaneous UseBrochure - Environmental XPRT
Donoghue Forlines LLC Acquires 2,755 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Burling Wealth Partners LLC - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Has $37.66 Million Holdings in Merck & Co., Inc. $MRK - MarketBeat
Belén Garijo’s prescription for Germany’s Merck - https-//www.semafor.com
Merck (MRK) Delivers Strong Q3 2025 Earnings as Oncology Sales Drive Revenue Growth - MSN
Scotiabank Begins Coverage on Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Thompson Davis & CO. Inc. Makes New $1.17 Million Investment in Merck & Co., Inc. $MRK - MarketBeat
Police & Firemen s Retirement System of New Jersey Raises Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck to Participate in the Jefferies Global Healthcare Conference in London - Business Wire
Scotiabank Initiates Merck & Co. at Sector Outperform With $105 Price Target - MarketScreener
Cherokee Insurance Co Buys New Position in Merck & Co., Inc. $MRK - MarketBeat
Candriam S.C.A. Sells 494,389 Shares of Merck & Co., Inc. $MRK - MarketBeat
Bailard Inc. Buys 9,336 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Boston Partners - MarketBeat
1 Incredible Reason to Buy LLY's Stock in November - The Motley Fool
Avalon Trust Co Has $1.49 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stake Lessened by Atlanta Consulting Group Advisors LLC - MarketBeat
Insider Sell: Cristal Downing Sells 7,085 Shares of Merck & Co I - GuruFocus
Merck & Co. Insider Sold Shares Worth $616,395, According to a Recent SEC Filing - MarketScreener
Geode Capital Management LLC Cuts Position in Merck & Co., Inc. $MRK - MarketBeat
Renasant Bank Purchases 7,966 Shares of Merck & Co., Inc. $MRK - MarketBeat
PNC Financial Services Group Inc. Reduces Holdings in Merck & Co., Inc. $MRK - MarketBeat
Kelleher Financial Advisors Has $816,000 Holdings in Merck & Co., Inc. $MRK - MarketBeat
United Asset Strategies Inc. Increases Position in Merck & Co., Inc. $MRK - MarketBeat
Tobam Sells 8,861 Shares of Merck & Co., Inc. $MRK - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Acquires 74,494 Shares of Merck & Co., Inc. $MRK - MarketBeat
M&G PLC Sells 85,084 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by KBC Group NV - MarketBeat
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):